KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $339.7 million.

  • Resmed's Cash from Operations rose 1008.41% to $339.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.9 billion, marking a year-over-year increase of 2968.13%. This contributed to the annual value of $1.8 billion for FY2025, which is 2500.09% up from last year.
  • According to the latest figures from Q4 2025, Resmed's Cash from Operations is $339.7 million, which was up 1008.41% from $457.3 million recorded in Q3 2025.
  • Resmed's 5-year Cash from Operations high stood at $578.7 million for Q1 2025, and its period low was -$65.7 million during Q3 2021.
  • Moreover, its 5-year median value for Cash from Operations was $277.7 million (2023), whereas its average is $270.9 million.
  • In the last 5 years, Resmed's Cash from Operations crashed by 14559.55% in 2021 and then soared by 54099.91% in 2023.
  • Quarter analysis of 5 years shows Resmed's Cash from Operations stood at $219.9 million in 2021, then crashed by 41.5% to $128.6 million in 2022, then soared by 112.1% to $272.8 million in 2023, then increased by 13.12% to $308.6 million in 2024, then increased by 10.08% to $339.7 million in 2025.
  • Its Cash from Operations stands at $339.7 million for Q4 2025, versus $457.3 million for Q3 2025 and $538.8 million for Q2 2025.